Tuesday, August 09, 2022 8:26:46 PM
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.
New York Yankees and Duke Basketball
Recent VRNA News
- Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 • GlobeNewswire Inc. • 05/02/2024 06:00:00 AM
- Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/25/2024 06:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/08/2024 09:18:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:40:38 AM
- Andrew Fisher Joins Verona Pharma as General Counsel • GlobeNewswire Inc. • 03/04/2024 07:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 11:08:57 AM
- Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 07:00:00 AM
- Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:11:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:10:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:19:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:07:24 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 11:02:48 AM
- Michael Austwick Joins Verona Pharma as Non-Executive Director • GlobeNewswire Inc. • 02/01/2024 07:00:00 AM
- Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:02:23 AM
- Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital • GlobeNewswire Inc. • 01/02/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:15:16 PM
- Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award • GlobeNewswire Inc. • 11/17/2023 07:00:00 AM
- Verona Pharma Announces November 2023 Investor Conference Participation • GlobeNewswire Inc. • 11/08/2023 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:11:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2023 12:09:56 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/03/2023 08:25:55 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM